87120-77-2

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-[(2-aminophenyl)amino]-, ethyl ester
• Synonyms: 1-Piperidinecarboxylic acid,4-[(2-aminophenyl)amino]-,ethyl ester;1-ethoxycarbonyl-4-(2-aminophenyl)aminopiperidine;4-(2-amino-phenylamino)-piperidine-1-carboxylic acid ethyl ester
• CAS NO: 87120-77-2
• Molecular Formula: C14H21N3O2
• Molecular Weight: 263.34
• Mol File: 87120-77-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 432.7±40.0 °C(Predicted)
• Density: 1.203±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-[(2-aminophenyl)amino]-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-[(2-aminophenyl)amino]-, ethyl ester(87120-77-2)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-[(2-aminophenyl)amino]-, ethyl ester(87120-77-2)

Safety Data

• Hazardous Substances Data: 87120-77-2(Hazardous Substances Data)

Usage

Structure

It is an ethyl ester derivative of 1-Piperidinecarboxylic acid, containing an amino group attached to a phenyl ring.

Usage

It is often used in medicinal chemistry and pharmaceutical research as a building block for the synthesis of various biologically active compounds, including potential drug candidates.

Functionality

The ethyl ester form allows for easier manipulation and modification of the molecule's chemical properties.

Versatility

It serves as a versatile intermediate for the development of new pharmaceuticals and industrial chemicals.

Upstream product

• 58859-46-4 ethyl 4-aminopiperidine-1-carboxylate 
• 1493-27-2 ortho-nitrofluorobenzene 
• 85443-52-3 ethyl 4-((2-nitrophenyl)amino)piperidine-1-carboxylate 

Downstream Products

• 1469924-37-5 C₂₉H₃₀FN₃O₃ 
• 1469924-36-4 C₂₃H₂₅Cl₂N₃O₃ 
• 1469924-52-4 C₂₆H₂₆FN₃O 
• 633310-75-5 C₃₈H₄₁FN₆O₂ 
• 1469924-51-3 C₂₀H₂₁Cl₂N₃O 
• 633310-74-4 C₃₂H₃₆Cl₂N₆O₂ 
• 1469924-67-1 C₄₈H₅₇FN₆O₆ 
• 1469924-66-0 C₄₂H₅₂Cl₂N₆O₆ 
• 57648-17-6 1-piperidin-4-yl-1,3-dihydro-benzoimidazole-2-thione 
• 53786-10-0 1,3-dihydro-1-methyl-3-(4-piperidinyl)-2H-benzimidazol-2-one 
• 400797-16-2 1-(1-{3-[5-acetyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxy-propyl}-piperidin-4-yl)-1,3-dihydro-benzoimidazol-2-one 

Relevant articles and documents

Novel BQCA- and TBPB-Derived M1 Receptor Hybrid Ligands: Orthosteric Carbachol Differentially Regulates Partial Agonism

Recently, investigations of the complex mechanisms of allostery have led to a deeper understanding of G protein-coupled receptor (GPCR) activation and signaling processes. In this context, muscarinic acetylcholine receptors (mAChRs) are highly relevant due to their exemplary role in the study of allosteric modulation. In this work, we compare and discuss two sets of putatively dualsteric ligands, which were designed to connect carbachol to different types of allosteric ligands. We chose derivatives of TBPB [1-(1′-(2-tolyl)-1,4′-bipiperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one] as M1-selective putative bitopic ligands, and derivatives of benzyl quinolone carboxylic acid (BQCA) as an M1 positive allosteric modulator, varying the distance between the allosteric and orthosteric building blocks. Luciferase protein complementation assays demonstrated that linker length must be carefully chosen to yield either agonist or antagonist behavior. These findings may help to design biased signaling and/or different extents of efficacy.

Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: Optimization of the 4-substituted piperidine

In our continuing effort to identify CGRP receptor antagonists for the acute treatment of migraine, we have undertaken a study to evaluate alternative 4-substituted piperidines to the lead dihydroquinazolinone 1. In this regard, we have identified the piperidinyl-azabenzimidazolone and phenylimidazolinone structures which, when incorporated into the benzodiazepine core, afford potent CGRP receptor antagonists (e.g., 18 and 29). These studies produced a potent analog (18) which overcomes the instability issues associated with the lead structure 1. A general pharmacophore for the 4-substituted piperidine component of these CGRP receptor antagonists is also presented.

Piperidines

Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-dependent sodium channels. More particularly, the invention provides substituted piperidines, and compositions containing these compounds. Also provided are methods using the compounds of the invention for the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrance of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a channel that includes a PN3 subunit.